MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Silence Therapeutics plc (NASDAQ: SLN)*
Organization & Developments: Silence Therapeutics
Parents
Silence Therapeutics plc (NASDAQ: SLN)*
Children
*Pioneers in the design and development of siRNAs (short interfering RNAs)
*Proprietary mRNAi GOLD™ platform consists of precision engineered product candidates designed to accurately target and 'silence' specific disease associated genes in the liver by using the body's natural process of RNAi (RNA interference).
2022: Silence sees fast-track tag as proof of FDA confidence in blood cancer drug that faced trial troubles
2022: Silence Therapeutics (SLN) Investor Presentation - Slideshow_seekingalpha.com
2024: Silence Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation
2025: Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)_ seekingalpha.com
Jumps
Finance & Acquisition: Silence Therapeutics
Key People: Silence Therapeutics